Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma

PURPOSE: This phase I trial was performed to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), preliminary efficacy, and pharmacokinetics (PK) of LY01610, a novel liposome-encapsulated irinotecan, in patients with advanced esophageal squamous cell carcinoma (ESCC). METHODS...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Chemother Pharmacol
Prif Awduron: Liu, Yun, Zhang, Bo, Xu, Jianping, Wang, Xingyuan, Tang, Jialin, Huang, Jing
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2021
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8143070/
https://ncbi.nlm.nih.gov/pubmed/34031756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-021-04294-2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg